Lōkahi Therapeutics™ Expands ai2 Pipeline™ Program Through Collaboration with Pepperdine E2B™

What was announced

Lōkahi Therapeutics announced a partnership with Pepperdine E2B to engage Pepperdine graduate students in its ai 2 Pipeline™ initiative during the upcoming academic year. The collaboration is structured as a hands-on project for full-time MBA students in a marketing course at the Pepperdine Graziadio Business School, where student teams will work with Lōkahi professionals to evaluate real therapeutic opportunities across scientific, regulatory, intellectual property, commercial, and strategic dimensions. The release emphasizes that the students will analyze actual therapeutic assets rather than hypothetical cases, and that the effort is intended both to expand Lōkahi’s sourcing reach and to provide educational experience for students.

Sources: S1

Relevant program context and prior results

The company described the ai 2 Pipeline™ and related ai 2 Futures Lab™ as having a first-year engagement that involved a cohort of students and produced a set of candidate assets now in further discussions. Lōkahi positions the ai 2 platform as combining human judgment with data, analytics, and technology to surface overlooked therapeutic opportunities.

Sources: S1

Why this may matter (inference)

The collaboration could increase Lōkahi’s analytical capacity and sourcing channels while providing Pepperdine students with applied experience in biopharma evaluation. For Lōkahi, structured university projects may supply additional dealflow and disciplined analysis for early-stage asset assessment; for students, the engagement provides exposure to interdisciplinary decision-making in the life sciences. These are inferences drawn from the program description and prior participation metrics reported by the company.

Sources: S1

What remains uncertain

• The announcement is a company press release and contains forward-looking statements that are qualified by the company; the partnership outcomes, student participation levels, and any advancement of identified assets are not independently verified in this release.
• The release does not specify contractual terms, financial commitments, or metrics for how assets identified through the program will be evaluated, acquired, or advanced beyond general descriptions of intent.